Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1904 combination therapy in CLDN18.2-positive advanced solid tumors
CTR20241158Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of garetatug rezetecan in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Jul 2024; status: active.
02
Drugs
garetatug rezetecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241158.